FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Clinical Hold on PepGen IND Application

[ Price : $8.95]

FDA places a clinical hold on a PepGen IND application for a Phase 1 trial of PGN-EDODM1 to treat myotonic dystrophy Type 1.

Precision BioSciences to Meet with FDA on Azer-Cel

[ Price : $8.95]

Precision BioScience says it will meet with FDA in June to discuss a regulatory way forward through a Phase 2 trial for its azer-c...

Groups Want Regulation of Lab-Developed Tests

[ Price : $8.95]

Sixteen advocacy organizations urge FDA to regulate laboratory-developed tests if Congress fails to produce a strong bill.

Junshi Bio Inspection to Advance Toripalimab BLA

[ Price : $8.95]

FDA completes a previously delayed pre-licensing inspection of China-based Shanghai Junshi Biosciences breakthrough cancer drug to...

FDA/EU MRA Now Includes Animal Inspections

[ Price : $8.95]

FDA and the European Union agree to expand the scope of the U.S.-EU mutual recognition agreement to include inspections of veterin...

FDA to Permit In-Person End-of-Phase 2 Meetings

[ Price : $8.95]

FDA says that beginning 6/12 it will expand in-person industry meetings to include requests for Type B End-of-Phase 2 requests at ...

FDA Proposes 1-Page Patient Medication Information

[ Price : $8.95]

FDA proposes a regulation to replace the current Medication Guides with a one-page Patient Medication Information sheet.

Violations at Advanced Compounding Solutions

[ Price : $8.95]

FDA warns Woburn, MA-based Advanced Compounding Solutions about multiple violations in its production of unapproved and misbranded...

Priority Review for BMS Lung Cancer Drug

[ Price : $8.95]

FDA accepts for priority review a Bristol Myers Squibb NDA for repotrectinib and its use for treating patients with ROS1-positive ...

Blue Earth PET Imaging Drug Approved

[ Price : $8.95]

FDA approves Blue Earth Diagnostics Posluma (flotufolastat F 18) injection, a prostate-specific membrane antigen-targeted positron...